Tysabri (natalizumab) is very effective for people with highly active relapsing remitting MS but it carries the risk of developing a rare but very serious brain infection called progressive multifocal leukoencephalopathy (PML).
The European Medicines Agency has recommended that a licence should be granted for Siponimod for the treatment of active secondary progressive MS.
On 3rd October we were excited to welcome two journalists to the Centre during our monthly Coffee Morning!
East Kent leads the way in robotic trials to improve patients’ mobility.
Swanley Therapy Centre held it’s annual Summer Fete fundraiser on the 8th June 2019. The event was a great success raising over £2,000 with over 120 attendees.
